Continuous subcutaneous insulin infusion therapy: A primer on insulin pumps

Journal of the American Pharmacists Association

Volumn 49, Issue 1, 2009, Pages

  Potti, Lakshmi G ^a   Haines, Stuart T ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Diabetes; Infusion devices; Insulin; Pharmacotherapy

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY OF LIFE; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INFUSIONS, SUBCUTANEOUS; INSULIN; INSULIN INFUSION SYSTEMS; QUALITY OF LIFE;

EID: 63849257428     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/JAPhA.2009.08122     Document Type: Article

References (46)

1. Walsh J, Roberts R. Pumping insulin. 4th ed. San Diego, CA: Torrey Pines Press; 2006.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-86.
3. Skyler JS, Ponder S, Kruger DF, Matheson D, Parkin CG. Is there a place for insulin pump therapy in your practice? Clin Diabetes. 2007;25:50-6.
4. Hirsch IB, Farkas-Hirsch R, Skyler JS. Intensive insulin therapy for treatment of type I diabetes. Diabetes Care. 1990;13:1265-83.
5. Polonsky KS, Given BD, Hirsch L, et al. Quantitative study of insulin secretion and clearance in normal and obese subjects. J Clin Invest. 1988;81:435-41.
6. Rasmussen H, Zawalich KC, Ganesan S, et al. Physiology and pathophysiology of insulin secretion. Diabetes Care. 1990;13:655-66.
7. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342:381-9.
8. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-53.
9. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care. 1999;22:99-111.
10. Nielsen FS, Jorgensen LN, Ipsen M, et al. Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen. Diabetologia. 1995;38:592-8.
11. Davey P, Grainger D, MacMillan J, et al. Clinical outcomes with insulin lispro compared with human regular insulin: a meta-analysis. Clin Ther. 1997;19:656-74.
12. Plank J, Siebenhofer A, Berghold A, et al. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med. 2005;165:1337-44.
13. Lock DR, Rigg LA. Hypoglycemic coma associated with subcutaneous insulin infusion by portable pump. Diabetes Care. 1981;4:389-91.
14. Hoogma RP, Hammond PJ, Gomis R, et al. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial. Diabet Med. 2006;23:141-7.
15. Hirsch IB, Bode BW, Garg S, et al. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. Diabetes Care. 2005;28:533-8.
16. Linkeschova R, Raoul M, Bott U, et al. Less severe hypoglycaemia, better metabolic control, and improved quality of life in type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy: an observational study of 100 consecutive patients followed for a mean of 2 years. Diabet Med. 2002;19:746-51.
17. Scheidegger U, Allemann S, Scheidegger K, Diem P. Continuous subcutaneous insulin infusion therapy: effects on quality of life. Swiss Med Wkly. 2007;137:476-82.
18. Gerich JE, Odawara M, Terauchi Y. The rationale for paired pre- and postprandial self-monitoring of blood glucose: the role of glycemic variability in micro- and macrovascular risk. Curr Med Res Opin. 2007;23:1791-8.
19. Monnier L, Colette C. Glycemic variability: should we and can we prevent it? Diabetes Care. 2008;31(suppl 2):S150-4.
20. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ. 2002;324:705.
21. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-20.
22. Heinecke JW. Oxidative stress: new approaches to diagnosis and prognosis in atherosclerosis. Am J Cardiol. 2003;91:12A-16A.
23. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes. 1995;44:968-83.
24. Hirsch IB, Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complications. 2005;19:178-81.
25. Kovatchev BP, Otto E, Cox D, et al. Evaluation of a new measure of blood glucose variability in diabetes. Diabetes Care. 2006;29:2433-8.
26. Ceriello A. Impaired glucose tolerance and cardiovascular disease: the possible role of post-prandial hyperglycemia. Am Heart J. 2004;147:803-7.
27. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001;161:397-405.
28. The DECODE Study Group, European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria: Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999;354:617-21.
29. Nakagami T. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia. 2004;47:385-94.
30. Shiraiwa T, Kaneto H, Miyatsuka T, et al. Post-prandial hyperglycemia is an important predictor of the incidence of diabetic microangiopathy in Japanese type 2 diabetic patients. Biochem Biophys Res Commun. 2005;336:339-45.
31. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;23(suppl 2):B21-9.
32. Tamborlane WV, Swan K, Sikes KA, et al. The renaissance of insulin pump treatment in childhood type 1 diabetes. Rev Endocr Metab Disord. 2006;7:205-13.
33. Lenhard MJ, Reeves GD. Continuous subcutaneous insulin infusion: a comprehensive review of insulin pump therapy. Arch Intern Med. 2001;161:2293-300.
34. Mecklenburg RS, Benson EA, Benson JW Jr, et al. Acute complications associated with insulin infusion pump therapy: report of experience with 161 patients. JAMA. 1984;252:3265-9.
35. Pietri A, Raskin P. Cutaneous complications of chronic continuous subcutaneous insulin infusion therapy. Diabetes Care. 1981;4:624-6.
36. Strowig SM. Initiation and management of insulin pump therapy. Diabetes Educ. 1993;19:50-9.
37. Bending JJ, Pickup JC. Complications of insulin infusion pump therapy. JAMA. 1985;253:2644-5.
38. Lauritzen T, Frost-Larsen K, Larsen HW, Deckert T. Effect of 1 year of near-normal blood glucose levels on retinopathy in insulin-dependent diabetics. Lancet. 1983;1:200-4.
39. Cogen FR, Streisand R, Sarin S. Selecting children and adolescents for insulin pump therapy: medical and behavioral considerations. Diabetes Spectrum. 2002;15:72-5.
40. Brink SJ, Stewart C. Insulin pump treatment in insulin-dependent diabetes mellitus: children, adolescents, and young adults. JAMA. 1986;255:617-21.
41. Kaufman FR, Halvorson M, Fisher L, Pitukcheewanont P. Insulin pump therapy in type 1 pediatric patients. J Pediatr Endocrinol Metab. 1999;12(suppl 3):759-64.
42. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care. 2008;31(suppl 1):S12-54.
43. Sigal RJ, Purdon C, Fisher SJ, et al. Hyperinsulinemia prevents prolonged hyperglycemia after intense exercise in insulin-dependent diabetic subjects. J Clin Endocrinol Metab. 1994;79:1049-57.
44. Shilo S, Sotsky M, Shamoon H. Islet hormonal regulation of glucose turnover during exercise in type 1 diabetes. J Clin Endocrinol Metab. 1990;70:162-72.
45. Hoelzer DR, Dalsky GP, Clutter WE, et al. Glucoregulation during exercise: hypoglycemia is prevented by redundant glucoregulatory systems, sympathochromaffin activation, and changes in islet hormone secretion. J Clin Invest. 1986;77:212-21.
46. Guinn TS, Bailey GJ, Mecklenburg RS. Factors related to discontinuation of continuous subcutaneous insulin-infusion therapy. Diabetes Care. 1988;11:46-51.